Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review From FDA
Grail, Inc.Grail, Inc.(US:GRAL) Barrons·2026-09-21 23:28

公司股价表现 - Grail股价在FDA会议前飙升33% [1] 公司核心事件 - Grail本周将与FDA会面，评估其多癌种血液检测产品的上市前批准申请 [1] - 该血液检测旨在早期发现多种癌症，被视为里程碑式产品 [1]

Grail, Inc.-Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review From FDA - Reportify